Literature DB >> 20410203

Chromogranin a and the autonomic system: decomposition of heart rate variability and rescue by its catestatin fragment.

Nagendu B Dev1, Jiaur R Gayen, Daniel T O'Connor, Sushil K Mahata.   

Abstract

Chromogranin A (CHGA/Chga) has been implicated in the genesis of systemic hypertension and consequent cardiac abnormalities. Catestatin (CST) (human CHGA(352-372)) replacement reduces blood pressure elevation and increases baroreflex sensitivity in Chga knockout (KO) mice. Because of the dampened baroreflex sensitivity, we reasoned that KO mice would display altered heart rate variability (HRV). Thus, we evaluated beat-to-beat measurements in HRV in wild-type (WT) and KO mice, before and after CST replacement. HR dynamics were evaluated by bipolar Einthoven electrocardiogram, with deconvolution into time and frequency domains, as well as Lorenz nonlinear return analyses. At baseline, HR was higher [444 +/- 24 beats per minute (bpm)] in KO compared with WT (330 +/- 18 bpm) mice. The total power in the HRV spectra was substantially diminished in KO animals. CST increased total power but only in KO mice. Each time-domain parameter was substantially lower in KO compared with WT mice, and the CST in the KO group could reverse the differences. Lorenz analysis revealed reductions in S1 (short axis perpendicular to the line of identity in the ellipse) and S2 (long axis along the line of identity in the ellipse) in KO animals, indicating that regulation of HRV is diminished in the parasympathetic and sympathetic domains. CST replacement caused restoration of both S1 and S2, in the KO group. These data suggest that Chga has a profound effect on autonomic tone to the heart and that its CST fragment is responsible for such actions. The results suggest future strategies for intervention in cardiovascular disorders accompanied by adverse HRV profiles.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20410203      PMCID: PMC2875835          DOI: 10.1210/en.2009-1110

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  49 in total

1.  Primary structure and function of the catecholamine release inhibitory peptide catestatin (chromogranin A(344-364)): identification of amino acid residues crucial for activity.

Authors:  S K Mahata; M Mahata; A R Wakade; D T O'Connor
Journal:  Mol Endocrinol       Date:  2000-10

Review 2.  Heart rate variability and cardiovascular mortality.

Authors:  Rollo P Villareal; Brant C Liu; Ali Massumi
Journal:  Curr Atheroscler Rep       Date:  2002-03       Impact factor: 5.113

Review 3.  The chromogranin-secretogranin family.

Authors:  Laurent Taupenot; Kimberly L Harper; Daniel T O'Connor
Journal:  N Engl J Med       Date:  2003-03-20       Impact factor: 91.245

4.  Evaluation of the role of I(KACh) in atrial fibrillation using a mouse knockout model.

Authors:  P Kovoor; K Wickman; C T Maguire; W Pu; J Gehrmann; C I Berul; D E Clapham
Journal:  J Am Coll Cardiol       Date:  2001-06-15       Impact factor: 24.094

5.  Phenotypic screening for heart rate variability in the mouse.

Authors:  J Gehrmann; P E Hammer; C T Maguire; H Wakimoto; J K Triedman; C I Berul
Journal:  Am J Physiol Heart Circ Physiol       Date:  2000-08       Impact factor: 4.733

6.  Association of hyperglycemia with reduced heart rate variability (The Framingham Heart Study).

Authors:  J P Singh; M G Larson; C J O'Donnell; P F Wilson; H Tsuji; D M Lloyd-Jones; D Levy
Journal:  Am J Cardiol       Date:  2000-08-01       Impact factor: 2.778

7.  Diagnostic value of the RR-variability indicators for mild hypertension.

Authors:  Mikhail Matveev; Rada Prokopova
Journal:  Physiol Meas       Date:  2002-11       Impact factor: 2.833

8.  Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension.

Authors:  Daniel T O'Connor; Mala T Kailasam; Brian P Kennedy; Michael G Ziegler; Noboru Yanaihara; Robert J Parmer
Journal:  J Hypertens       Date:  2002-07       Impact factor: 4.844

9.  Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality.

Authors:  C Ceconi; R Ferrari; T Bachetti; C Opasich; M Volterrani; B Colombo; G Parrinello; A Corti
Journal:  Eur Heart J       Date:  2002-06       Impact factor: 29.983

10.  Altered baroreflex control of heart rate in bradykinin B2-receptor knockout mice.

Authors:  P Madeddu; M B Salis; C Emanueli
Journal:  Immunopharmacology       Date:  1999-12
View more
  16 in total

1.  Catestatin (chromogranin A(352-372)) and novel effects on mobilization of fat from adipose tissue through regulation of adrenergic and leptin signaling.

Authors:  Gautam K Bandyopadhyay; Christine U Vu; Stefano Gentile; Howon Lee; Nilima Biswas; Nai-Wen Chi; Daniel T O'Connor; Sushil K Mahata
Journal:  J Biol Chem       Date:  2012-04-25       Impact factor: 5.157

2.  A novel catestatin-induced antiadrenergic mechanism triggered by the endothelial PI3K-eNOS pathway in the myocardium.

Authors:  Eleonora Bassino; Sara Fornero; Maria Pia Gallo; Roberta Ramella; Sushil K Mahata; Bruno Tota; Renzo Levi; Giuseppe Alloatti
Journal:  Cardiovasc Res       Date:  2011-05-04       Impact factor: 10.787

3.  Autonomic and hemodynamic origins of pre-hypertension: central role of heredity.

Authors:  Jason T Davis; Fangwen Rao; Dalal Naqshbandi; Maple M Fung; Kuixing Zhang; Andrew J Schork; Caroline M Nievergelt; Michael G Ziegler; Daniel T O'Connor
Journal:  J Am Coll Cardiol       Date:  2012-06-12       Impact factor: 24.094

4.  Impact of Chromogranin A deficiency on catecholamine storage, catecholamine granule morphology and chromaffin cell energy metabolism in vivo.

Authors:  Teresa Pasqua; Sumana Mahata; Gautam K Bandyopadhyay; Angshuman Biswas; Guy A Perkins; Amiya P Sinha-Hikim; David S Goldstein; Lee E Eiden; Sushil K Mahata
Journal:  Cell Tissue Res       Date:  2015-11-16       Impact factor: 5.249

5.  Cardiac electrical activity in a genomically "humanized" chromogranin a monogenic mouse model with hyperadrenergic hypertension.

Authors:  Nagendu B Dev; Saiful A Mir; Jiaur R Gayen; Jawed A Siddiqui; Maja Mustapic; Sucheta M Vaingankar
Journal:  J Cardiovasc Transl Res       Date:  2014-05-13       Impact factor: 4.132

Review 6.  Glycosylated Chromogranin A: Potential Role in the Pathogenesis of Heart Failure.

Authors:  Anett H Ottesen; Geir Christensen; Torbjørn Omland; Helge Røsjø
Journal:  Curr Heart Fail Rep       Date:  2017-12

7.  Analysis and validation of traits associated with a single nucleotide polymorphism Gly364Ser in catestatin using humanized chromogranin A mouse models.

Authors:  Saiful A Mir; Kuixing Zhang; Milos Milic; Yusu Gu; Timo Rieg; Michael Ziegler; Sucheta M Vaingankar
Journal:  J Hypertens       Date:  2016-01       Impact factor: 4.844

Review 8.  Disorders of blood pressure regulation-role of catecholamine biosynthesis, release, and metabolism.

Authors:  Gemma Currie; E Marie Freel; Colin G Perry; Anna F Dominiczak
Journal:  Curr Hypertens Rep       Date:  2012-02       Impact factor: 5.369

9.  Catecholamine storage vesicles: role of core protein genetic polymorphisms in hypertension.

Authors:  Kuixing Zhang; Yuqing Chen; Gen Wen; Manjula Mahata; Fangwen Rao; Maple M Fung; Sucheta Vaingankar; Nilima Biswas; Jiaur R Gayen; Ryan S Friese; Sushil K Mahata; Bruce A Hamilton; Daniel T O'Connor
Journal:  Curr Hypertens Rep       Date:  2011-02       Impact factor: 5.369

10.  Catestatin improves post-ischemic left ventricular function and decreases ischemia/reperfusion injury in heart.

Authors:  Claudia Penna; Giuseppe Alloatti; Maria Pia Gallo; Maria Carmela Cerra; Renzo Levi; Francesca Tullio; Eleonora Bassino; Serena Dolgetta; Sushil K Mahata; Bruno Tota; Pasquale Pagliaro
Journal:  Cell Mol Neurobiol       Date:  2010-11-23       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.